Background There is an emerging need to develop consistent outcomes in clinical trials to allow effective comparison of treatment effects. No systematic review has previously looked at the reporting of outcome measures used in randomized controlled trials (RCTs) on the treatment and prevention of cellulitis (erysipelas). Objectives The primary aim of this review was to describe the breadth of outcomes reported from RCTs on cellulitis treatment and prevention. The secondary aim was to identify outcome themes from patients' and healthcare professionals' feedback from a cellulitis Priority Setting Partnership (PSP). Methods We conducted a review of all outcome measures used in RCTs from two recent Cochrane reviews. Free-text responses from a cellulitis priority setting survey were used to understand the perspectives of patients and healthcare professionals. Results Outcomes from 42 RCTs on treatment of cellulitis and six RCTs on prevention of cellulitis were reviewed. Only 28 trials stated their primary outcome. For trials assessing treatment of cellulitis, clinical response to treatment was categorized in 25 different ways. Five of these trials used an outcome that was in accordance with FDA guidance and only four trials incorporated either quality of life or patient satisfaction. For trials assessing prevention of cellulitis, recurrence was the key outcome measure. From the cellulitis PSP, prevention of recurrence, clinical features and long-term disease impact were the most important outcome themes for patients. Conclusions We have shown that in cellulitis treatment and prevention research, there is significant heterogeneity in clinical outcomes, inadequate focus on patient-reported outcomes, and a disparity between what is currently measured and what patients and healthcare professionals feel is important. We recommend that future cellulitis treatment trials consider the use of longer-term outcomes to capture recurrence and long-term morbidity, as well as short-term resolution of acute infection.
What does this study add?
• This review is the first to combine and compare clinical outcomes in randomized controlled trials (RCTs) assessing treatment and prevention of cellulitis with outcome themes deemed important to patients and healthcare professionals.
• We have highlighted the disparity in clinical outcomes published in these RCTs and the lack of patient-reported outcomes.
• Following the COMET initiative, we suggest that homogeneous outcomes should be sought and specified for future research in cellulitis.
Cellulitis is an acute, potentially serious bacterial infection of the cutaneous and subcutaneous tissue, usually occurring on the lower limb. The most common causative organism is group A streptococcus (Streptococcus pyogenes), 1 which causes a spreading area of erythema, tenderness and swelling. The illness can be complicated by ulceration and purulence, and progression to systemic disease in severe cases. Erysipelas is characterized by a superficial, well-demarcated area of inflammation, while cellulitis often extends to the subcutaneous tissue. 2 It is often difficult to distinguish between them clinically; therefore, for the purpose of this review we have used cellulitis as the umbrella term for cellulitis, erysipelas and skin and softtissue infection, to reflect current practice. Cellulitis poses a significant health burden to the National Health Service: during 2014-15 in England, 114 190 patients were treated in hospital for cellulitis, with a median length of hospital stay of 6 days. 3 In addition to short-term signs and symptoms, the disease can have a significant long-term impact on patients' physical and mental health. 4 In certain groups of patients there are high levels of recurrence of cellulitis arising from repeated damage to the lymphatic system and the presence of certain risk factors. 2 Despite the impact of the disease, there are few well-conducted trials looking into the treatment and prevention of cellulitis. 5, 6 It has been reported that clinical assessment of cellulitis many not capture the patient's experience, and may be unreliable in reflecting real effects for patients. 7 Defining standard, measurable outcomes is essential for well-designed, robust clinical trials, to provide trial results that can be reliably compared. 8 Outcomes need to be meaningful and relevant for service users, including patients and clinicians, in order to make a long-term difference to future practice. It has been recognized that many outcomes in clinical trials lack sufficient validation, and there is support for development of core outcome sets for trials to address this issue, as proposed by the COMET initiative. 8 A core outcome set is an agreed set of outcomes that should be measured and reported, as a minimum, in all clinical trials in a specific area of health care. 9 The initial stage in developing a core outcome set is to identify what outcomes are available, and to establish which are the most important and relevant for healthcare users. 10, 11 The U.S. Food and Drug Administration (FDA) have attempted to address the lack of consistent outcomes for clinical trials of acute bacterial skin and soft-tissue infections. In 2013 they updated their guidance on end points in such trials, which states that the primary outcome should be ʻ% reduction in lesion size, measured at 48 to 72 h compared to baselineʼ. 12 However, this recommendation is based largely on historical trial data dating to the preantibiotic era and has undergone incomplete validation. 13 There have been no systematic reviews assessing outcome measures used in cellulitis trials. The main aim of this review was to describe all the outcome measures reported in randomized control trials (RCTs) on the treatment and prevention of cellulitis. The secondary aim was to identify outcome themes from patients' and healthcare professionals' feedback from a cellulitis Priority Setting Partnership (PSP). 14 
Methods
Study 1: review of outcome measures in randomized controlled trials for the treatment and prevention of cellulitis
Search strategy
This review included all RCTs that were included in two Cochrane reviews: 'interventions for the prevention of recurrent erysipelas and cellulitisʼ, 5 published in June 2017, and the Cochrane update: 'interventions for the treatment of cellulitis and erysipelas' (awaiting publication but obtained from personal communication with the authors). Studies that assessed treatment or prevention of cellulitis, erysipelas or skin and soft-tissue infection were included in this review. A search of COMET and PROS-PERO was performed to ensure that no existing core outcome initiatives of thematically similar reviews were already registered. Data regarding treatment complications, adverse events and side-effects were not collected, as these data are routinely collected in drug trials and were not an aim of this review.
The study protocol for this review is available to view on the Centre of Evidence Based Dermatology website. 15 Data extraction and assessment of bias Reported outcomes were extracted using a standardized template that was piloted prior to use. If the outcome measures were not clearly stated in the methods section of the trial report, but were described in the results section, then these were included.
Details of outcome measures were extracted from each paper by two independent researchers (E.S. and M.P.). Any disagreements were resolved by two further independent researchers. Data extracted were (i) demographics of the trial (authors and date of publication); (ii) trial type: treatment or prevention of cellulitis, drug or nondrug; (iii) whether the primary outcome was stated; (iv) the total number of outcomes per trial; (v) whether the outcomes were in line with the FDA guidance on skin infections; (vi) additional comments on outcomes used in trials (e.g. justification of outcomes); (vii) broad outcome domains: clinical, microbiological, biochemical, treatment related, patient focused, additional outcomes. For each outcome domain, further definitions were used for the specific outcomes measured (e.g. cure, failure or response, length of hospital stay, quality of life). Additionally, for clinical outcome, the specific clinical features that were assessed as part of the outcome were identified (e.g. erythema, swelling, warmth); (viii) definition of each outcome; (ix) how the outcome was assessed; (x) scales used; (xi) outcome assessor (e.g. nurse, clinician or patient); and (xii) timing and frequency of assessment.
Storage and analysis of all the data were undertaken by the lead researcher (E.S.) using Microsoft Excel, 2010, at the Centre of Evidence Based Dermatology. Data are presented descriptively, and results reported separately for cellulitis treatment trials and prevention trials.
Study 2: understanding patients' and healthcare professionals' perspectives
Using free-text data collected during a priority setting 14 we sought to identify outcomes of importance to patients and healthcare professionals. Responses were submitted by 401 survey participants (171 patients or carers, 217 healthcare professionals, 13 other). Participants were asked the following: 'What questions about the diagnosis, treatment or prevention of cellulitis would you like to see answered by research?' Data relevant to outcome measurement were extracted from the free-text responses and used to identify key outcome themes using the word repetition technique. 16 
Results
From the two Cochrane reviews, 48 trials were identified and included in the final analysis. This included 42 RCTs assessing acute treatment of cellulitis and six RCTs assessing prevention of cellulitis. No studies were excluded. The total number of outcomes measured per trial ranged from one to eight, across six different outcome domains (Fig. 1) . Only 28 trials (58%) stated the primary outcome. Two papers assessed nonpharmacological treatments for cellulitis: one reviewed the use of vibration therapy and the other an alternative therapy (sodium selenite). Six trials evaluated treatment strategies for skin and soft-tissue infections but did not analyse results for cellulitis separately. However, data from these papers were included in this review, to maximize capture of outcomes.
Randomized controlled trials assessing treatment of cellulitis

Clinical outcomes
All trials assessed at least one clinical outcome. Of the RCTs assessing treatment of cellulitis, clinical response was categorized according to a range of definitions (Table S1 and Appendix S1; see Supporting Information), with the majority of papers classifying response according to 'cure', 'failure' or 'improvement'. The timing of the clinical assessment was variable. Some recent trials assessed clinical response at an early time point, 2-3 days after treatment initiation. However, most trials assessed response at a 'test-of-cure' visit, which ranged from 2 to 42 days after the end of treatment (Table S1) . A successful clinical response or 'cure' was defined most commonly as either 'complete resolution of presenting signs and symptoms' or 'resolution of the infection/improvement to such an extent that no further antimicrobial therapy was necessary' (Table S2 ; see Supporting Information). Four trials (10%) included 'absence of recurrence' of infection as part of the definition of a successful clinical response. There were 10 different signs and symptoms of infection used to describe clinical response across the trials (Fig. 2) . The most commonly assessed clinical feature was erythema. Of 34 trials that assessed erythema, six (18%) assessed this numerically, measuring the diameter or area of erythema, six (18%) graded the erythema on a severity scale (Fig. 3) and 13 (38%) used 'clinical assessment/evaluation' without further detail of the methods used.
Sixteen trials (38%) assessed at least one biochemical marker as part of the clinical response to treatment. Of these, the most commonly assessed markers were white cell count, erythrocyte sedimentation rate and C-reactive protein.
Microbial outcomes
Twenty-four trials (57%) included a microbial outcome, assessed using either blood or wound culture. The majority of trials categorized microbial response according to 'complete/ presumed eradication', 'persistence/presumed persistence' and 'indeterminate/not evaluable' (Table S3 ; see Supporting Information). Of the trials assessing a microbial response, the timing and frequency of assessment were either not stated or unclear in 18 trials (42%).
Treatment-related outcomes
Sixteen trials (38%) assessed a treatment-related outcome. These included duration of antibiotic treatment (13), number of doses of antibiotic (two) and serum antibiotic concentration (one). One trial used 'number of doses of antibiotic until clinical response' as the primary outcome for the study.
Patient-focused outcomes
Four trials included patient-focused outcomes in their methodology. One trial assessed quality of life using the EuroQol-5 dimensions (EQ-5D) questionnaire. Two assessed patients' impressions of improvement of cellulitis: one used the patient Global Impression of Improvement scale and one used predefined categorical statements: improved, stayed the same, worsened. One paper assessed patient satisfaction with treatment received, assessing each of three parameters (convenience, effectiveness and overall satisfaction) on a scale of 0-4. Eleven trials (26%) assessed patient-reported pain (Table S4 ; see Supporting Information).
Food and Drug Administration guidance
Five trials (12%) assessing treatment of cellulitis that were published from 2011 onwards had their primary outcome in line with FDA guidance.
Randomized controlled trials assessing prevention of cellulitis
The primary outcome of trials assessing prevention of cellulitis was either 'number of episodes of recurrence' or 'time to recurrence' of cellulitis for all six RCTs. [17] [18] [19] [20] [21] [22] Three (50%) of the trials specified the clinical features to be used in assessing an episode of recurrence. The follow-up time varied from 3 months to 3 years. Two papers (33%) explained how patients were monitored during the follow-up period: via routine telephone calls, 3 monthly during the treatment phase and 6 monthly during the follow-up phase. It is worth noting that the PATCH I and II trials intended to collect data on the impact of cellulitis on quality of life; however, this was abandoned due to technical difficulties around the timing of assessments in recurrent episodes. 21 
Additional outcomes
Additional outcomes measured in all trials (assessing both treatment and prevention of cellulitis) included length of hospital stay (10 trials) and cost-related outcomes (five trials).
Outcome themes from the cellulitis Priority Setting Partnership
In total 846 uncertainties were submitted during the PSP survey. These data were reviewed for outcome themes, and 254 responses (30%) included reference to outcomes of importance to the participant. From these responses, 263 outcome themes were identified (some responses contained more than one outcome theme), of which 73 (28%) were from patients and 190 (72%) from healthcare professionals. 'Prevention of recurrence' was the most frequently stated outcome theme of importance from both patients and healthcare professionals (Fig. 4) . Treatment-focused outcomes such as length of acute and prophylactic antibiotic therapy, and the use of objective markers to assess treatment response, were also key priorities for healthcare professionals. Assessment of clinical features (most commonly erythema, swelling and pain) and long-term morbidity and mortality were the next most important outcomes for patients. Surprisingly, only 2% of all outcome themes extracted focused on patient-oriented factors such as quality of life and treatment satisfaction.
Discussion
This review highlights the significant variation of outcomes that are currently used in cellulitis trials, suggesting that efforts to streamline and develop a consensus-driven core outcome set would be valuable. Clinical response to treatment was categorized in 25 different ways in the 42 treatment trials, and 'cure', 'success' or 'resolution' had 18 different definitions that were measured over a range of time scales, from 2 to 35 days after the end of treatment. The majority of trials defined 'cure' according to 'complete or partial resolution of presenting signs and symptoms of infection'. However, the specific signs and symptoms of infection assessed, such as erythema, swelling and warmth, were often poorly defined. Up to 10 different signs and symptoms of infection were each used by at least one trial to assess treatment response. This reflects the general lack of consensus in outcome assessment for cellulitis.
Some of the more recent trials used 'early clinical response' as the primary outcome, defined as the cessation of lesion spread (measured as the length 9 width of lesion) 48-72 h after treatment initiation. Assessing treatment response at this earlier time point may increase the reliability of the measurement of drug effect, because the outcome is not confounded by natural improvement of disease. 23 Moreover, this end point is in line with the 2013 FDA guidance recommending early clinical response as the primary outcome. 12 Patient-focused outcomes such as patient-reported pain, treatment satisfaction and quality of life were rarely reported. We know that cellulitis has a significant impact on physical and psychological health, as well as activities of daily living and quality of life, 4 yet this significance is not reflected in the outcomes from the cellulitis trials published to date. Importantly, the survey results suggest that recurrence and long-term disease impact are important aspects to patients. To date, treatment trials have tended to be of short duration and have focused on resolution of symptoms associated with the acute episode. This is not surprising given the cost and methodological complexities associated with longer-term trials, but may require greater consideration when planning future studies. There were far more treatment trials than prevention trials, which again suggests an imbalance favouring short-term outcomes. More trials that address the prevention of long-term morbidity and recurrence are needed, so that treatment strategies can be developed that have a long-term beneficial impact for patients.
In contrast to patient responses, the survey results revealed that the most important outcomes to healthcare professionals were objective markers of disease response, length of antibiotic treatment and prophylaxis (in addition to recurrence). This is perhaps not surprising, given that healthcare professionals are responsible for both prescribing and objective assessment of treatment effect, rather than having a subjective experience of disease.
The use of blood or wound cultures in cellulitis management is debatable. Microbial outcomes are a poor indicator of treatment success as their yield is often low, even in the presence of infection, 24 and they can be adversely affected if patients have been pretreated with antibiotics. Furthermore, microbial cultures do not correlate well with severity of signs and symptoms or patient experience. 24 This outcome measure is also of limited relevance to patients. However, the increasing incidence of antimicrobial resistance means that other indicators of resistance, such as the incidence and severity of other bacterial infections, may be important to collect. This review summarized the breadth of outcomes reported in published RCTs and analysed these alongside outcomes considered important by patients and healthcare professionals. As data on the views of patients and healthcare professionals were originally collected for another purpose (defining the research agenda for cellulitis research), they may be less reflective of the results than if respondents had been asked specifically about research outcomes. Further qualitative work is required to replicate our findings and to ascertain fully the perspectives of all key stakeholders.
The quality of the included studies was not assessed as this was not the aim of this review; however, many studies were poorly reported, making it difficult at times to establish a detailed understanding of the outcome measures used.
Due to time and resource limitations, the included studies were identified from two recently updated Cochrane reviews. These were chosen because they are both up to date and sufficiently broad (covering any 'treatment' and 'prevention' of cellulitis) to gain the breadth of outcome data we aimed to capture. It is possible that more recent RCTs on cellulitis treatment and prevention have since been published.
Of the included trials eight were conducted in single countries and nine in multiple countries. This review captures a representative snapshot of existing outcome measures used in cellulitis research. Others have highlighted similar variability in outcome measure instruments used in skin diseases such as eczema, 25 vitiligo 26 and acne. 27 In conclusion, outcome measures for cellulitis should not only be consistent, to allow clinical trials to be adequately compared, but should also be reflective of the real impact on patients' day-to-day lives. This review has highlighted that in cellulitis research currently there is a lack of consensus over what should be measured, how it should be measured and over what time frame. Future research should work towards validating current outcomes with a view to developing a core outcome set for cellulitis. Ideally this would include patientreported outcomes and a long-term outcome measure, such as recurrence, to account for the chronicity of the disease, which is important to many patients. Currently, researchers should seek to ensure that the outcomes measured are in line with FDA guidance specific to acute bacterial skin and soft-tissue infections.
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